Recent advances in clinical practice challenges and opportunities in the management of obesity

Gut

Volumn 63, Issue 4, 2014, Pages 687-695

  Acosta, Andres ^a   Dayyeh, Barham K Abu ^a   Port, John D ^b   Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; GHRELIN; INCRETIN; NEUROHORMONE;

ADIPOCYTE; ARTICLE; AUTONOMIC DENERVATION; BARIATRIC SURGERY; BRAIN STEM; CARDIA; CENTRAL NERVOUS SYSTEM; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMORBIDITY; DISEASE ASSOCIATION; FOOD INTAKE; GASTRIC BANDING; GASTROSTOMY; HEALTH CARE COST; HUMAN; HYPOTHALAMUS NUCLEUS; INTESTINE BYPASS; LIFESTYLE MODIFICATION; MICROBIOME; OBESITY; PATHOPHYSIOLOGY; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; STOMACH BYPASS; VAGUS NERVE; WEIGHT REDUCTION;

BRAIN/GUT INTERACTION; GASTROINTESTINAL HORMONES; OBESITY;

BARIATRIC SURGERY; CENTRAL NERVOUS SYSTEM; HUMANS; INCRETINS; MICROBIOTA; OBESITY; WEIGHT REDUCTION PROGRAMS;

EID: 84895461525     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306235     Document Type: Article

References (115)

1. Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001;74:579-84. (Pubitemid 33015142)
2. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273:219-34.
3. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. N Engl J Med 2013;369:145-54.
4. Pi-Sunyer FX, Becker DM, Bouchard C, et al. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary. Am J Clin Nutr 1998;68:899-917. (Pubitemid 28471075)
5. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
6. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30:1374-83. (Pubitemid 46871141)
7. Sohn JW, Xu Y, Jones JE, et al. Serotonin 2C receptor activates a distinct population of arcuate pro-opiomelanocortin neurons via TRPC channels. Neuron 2011;71:488-97.
8. Smith S, Weissman N, Anderson C, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-56.
9. Allison D, Gadde K, Garvey W, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring, Md) 2012;20:330-42.
10. Thomsen W, Grottick A, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325:577-87. (Pubitemid 351574813)
11. Nichols D. Hallucinogens. Pharmacol Ther 2004;101:131-81. (Pubitemid 38167565)
12. Devereux R. Appetite suppressants and valvular heart disease. N Engl J Med 1998;339:765-6.
13. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT (2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81. (Pubitemid 30033262)
14. Launay JM, Hervé P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8:1129-35. (Pubitemid 35175968)
15. FDA approves weight-management drug Qsymia. In: Administration USFaD, ed., 2012.
16. Buchwald H, Williams SE. Bariatric surgery worldwide 2003. Obes Surg 2004;14:1157-64. (Pubitemid 39458587)
17. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009;19:1605-11.
18. Buchwald H, Oien D. Metabolic/Bariatric surgery worldwide 2011. Obes Surg 2013;23:427-36.
19. Banks W. The blood-brain barrier: connecting the gut and the brain. Regul Pept 2008;149:11-14.
20. Hileman S, Pierroz D, Masuzaki H, et al. Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 2002;143:775-83. (Pubitemid 34164025)
21. Lenard NR, Berthoud H-R. Central and Peripheral Regulation of Food Intake and Physical Activity: Pathways and Genes. Obesity 2008;16:S11-22.
22. Gardiner JV, Jayasena CN, Bloom SR. Gut hormones: a weight off your mind. J Neuroendocrinol 2008;20:834-41. (Pubitemid 351858737)
23. Baynes KC, Dhillo WS, Bloom SR. Regulation of food intake by gastrointestinal hormones. Curr Opin Gastroenterol 2006;22:626-31. (Pubitemid 44624529)
24. Cone RD, Cowley MA, Butler AA, et al. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001;25(Suppl 5):S63-7. (Pubitemid 34146326)
25. Cowley MA. Hypothalamic melanocortin neurons integrate signals of energy state. Eur J Pharmacol 2003;480:3-11. (Pubitemid 37410356)
26. Grill HJ. Distributed neural control of energy balance: contributions from hindbrain and hypothalamus. Obesity (Silver Spring) 2006;14(Suppl 5):216S-21S.
27. Hillebrand JJ, De Wied D, Adan RA. Neuropeptides, food intake and body weight regulation: a hypothalamic focus. Peptides 2002;23:2283-306. (Pubitemid 36092065)
28. Heijboer AC, Pijl H, Van Den Hoek AM, et al. Gut-brain axis: regulation of glucose metabolism. J Neuroendocrinol 2006;18:883-94. (Pubitemid 44660622)
29. Smith G. The direct and indirect controls of meal size. Neurosci Biobehav Rev 1996;20:41-6. (Pubitemid 126682110)
30. Berthoud H-R. The vagus nerve, food intake and obesity. Regul Pept 2008;149:15-25.
31. Azzara A, Sokolnicki J, Schwartz G. Central melanocortin receptor agonist reduces spontaneous and scheduled meal size but does not augment duodenal preload-induced feeding inhibition. Physiol Behav 2002;77:411-16. (Pubitemid 35373896)
32. Ste Marie L, Miura G, Marsh D, et al. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci USA 2000;97:12339-44.
33. Williams D, Kaplan J, Grill H. The role of the dorsal vagal complex and the vagus nerve in feeding effects of melanocortin-3/4 receptor stimulation. Endocrinology 2000;141:1332-7. (Pubitemid 32269100)
34. Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008;18:158-68. (Pubitemid 351282471)
35. Stice E, Spoor S, Ng J, et al. Relation of obesity to consummatory and anticipatory food reward. Physiol Behav 2009;97:551-60.
36. Di Leone RJ, Taylor JR, Picciotto MR. The drive to eat: comparisons and distinctions between mechanisms of food reward and drug addiction. Nat Neurosci 2012;15:1330-5.
37. Aponte Y, Atasoy D, Sternson S. AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training. Nat Neurosci 2011;14:351-5.
38. Williams K, Elmquist J. Lighting up the hypothalamus: coordinated control of feeding behavior. Nat Neurosci 2011;14:277-8.
39. Page K, Chan O, Arora J, et al. Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways. JAMA 2013;309:63-70.
40. Page K, Arora J, Qiu M, et al. Small decrements in systemic glucose provoke increases in hypothalamic blood flow prior to the release of counterregulatory hormones. Diabetes 2009;58:448-52.
41. Monet P, Franc J, Brasseur A, et al. [Arterial spin labeling: state of the art]. J Radiol 2009;90:1031-7.
42. Paulsen S, Larsen L, Jelsing J, et al. Gene expression profiling of individual hypothalamic nuclei from single animals using laser capture microdissection and microarrays. J Neurosci Methods 2009;177:87-93.
43. Shin A, Berthoud H-R. Obesity surgery: happy with less or eternally hungry? Trends Endocrinol Metab 2013;24:101-8.
44. Müller M, Bosy-Westphal A, Heymsfield S. Is there evidence for a set point that regulates human body weight? F1000 Med Rep 2010;2:59.
45. Stefater M, Pérez-Tilve D, Chambers A, et al. Sleeve gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity. Gastroenterology 2010;138:2426.
46. Nadreau E, Baraboi ED, Samson P, et al. Effects of the biliopancreatic diversion on energy balance in the rat. Int J Obes (Lond) 2006;30:419-29.
47. Warne J, Padilla B, Horneman H, et al. Metabolic and neuroendocrine consequences of a duodenal-jejunal bypass in rats on a choice diet. Ann Surg 2009;249:269-76.
48. Romanova I, Ramos E, Xu Y, et al. Neurobiologic changes in the hypothalamus associated with weight loss after gastric bypass. J Am Coll Surg 2004;199:887-95. (Pubitemid 39539236)
49. Fry M, Hoyda TD, Ferguson AV. Making sense of it: roles of the sensory circumventricular organs in feeding and regulation of energy homeostasis. Exp Biol Med (Maywood) 2007;232:14-26. (Pubitemid 46089937)
50. Halatchev I, Cone R. Peripheral administration of PYY (3-36) produces conditioned taste aversion in mice. Cell Metab 2005;1:159-68. (Pubitemid 43960603)
51. Camilleri M, Toouli J, Herrera M, et al. Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device. Surgery 2008;143:723-31.
52. Browning KN, Fortna SR, Hajnal A. Roux-en-Y gastric bypass reverses the effects of diet-induced obesity to inhibit the responsiveness of central vagal motoneurones. J Physiol 2013;591:2357-72.
53. Nestoridi E, Kvas S, Kucharczyk J, et al. Resting energy expenditure and energetic cost of feeding are augmented after Roux-en-Y gastric bypass in obese mice. Endocrinology 2012;153:2234-44.
54. Ochner CN, Kwok Y, Conceicao E, et al. Selective reduction in neural responses to high calorie foods following gastric bypass surgery. Ann Surg 2011;253:502-7.
55. Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009;150:2518-25.
56. Phillips RJ, Powley TL. Gastric volume rather than nutrient content inhibits food intake. Am J Physiol 1996;271:R766-9.
57. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60. (Pubitemid 129516334)
58. Delhanty P, Neggers S, Van Der Lely A. Mechanisms in endocrinology: Ghrelin: the differences between acyl- and des-acyl ghrelin. Eur J Endocrinol 2012;167:601-8.
59. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30. (Pubitemid 34755670)
60. Fruhbeck G, Diez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med 2004;350:308-9. (Pubitemid 38067650)
61. Silk DB, Webb JP, Lane AE, et al. Functional differentiation of human jejunum and ileum: a comparison of the handling of glucose, peptides, and amino acids. Gut 1974;15:444-9.
62. Wang P, Caspi L, Lam C, et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 2008;452:1012-16. (Pubitemid 351589616)
63. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006;244:741-9. (Pubitemid 44629948)
64. Klein S, Fabbrini E, Patterson BW, et al. Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. Obesity 2012;20:1266-72.
65. Geloneze B, Geloneze SR, Fiori C, et al. Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. Obes Surg 2009;19:1077-83.
66. Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology 2012;143:897-912.
67. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-76.
68. Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009;250:234-41.
69. Lee W-J, Chong K, Ser K-H, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011;146:143-8.
70. Shah P, Todkar J, Shah S. Effectiveness of laparoscopic sleeve gastrectomy on glycemic control in obese Indians with type 2 diabetes mellitus. Surg Obes Relat Dis 2010;6:138-41.
71. Gill R, Birch D, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis 2010;6:707-13.
72. Li P, Fu P, Chen J, et al. Laparoscopic Roux-en-Y gastric bypass vs. laparoscopic sleeve gastrectomy for morbid obesity and diabetes mellitus: a meta-analysis of sixteen recent studies. Hepatogastroenterology 2013;60:132-7.
73. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007;117:13-23. (Pubitemid 46048445)
74. Jang HJ, Kokrashvili Z, Theodorakis MJ, et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 2007;104:15069-74. (Pubitemid 47619594)
75. Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006;290:E550-9. (Pubitemid 43671703)
76. Rogers G, Tolhurst G, Ramzan A, et al. Electrical activity-triggered glucagon-like peptide-1 secretion from primary murine L-cells. J Physiol 2011;589:1081-93.
77. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20. (Pubitemid 28084232)
78. Orskov C, Holst J, Nielsen O. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988;123:2009-13.
79. Marathe C, Rayner C, Jones K, et al. Glucagon-like peptides 1 and 2 in health and disease: a review. Peptides 2013;44:75-86.
80. Toft-Nielsen M, Damholt M, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23. (Pubitemid 32755966)
81. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340-8.
82. Laferrere B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30:1709-16. (Pubitemid 47036341)
83. Korner J, Bessler M, Inabnet W, et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007;3:597-601. (Pubitemid 350091417)
84. Strader A, Clausen T, Goodin S, et al. Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats. Obes Surg 2009;19:96-104.
85. Cummings B, Strader A, Stanhope K, et al. Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology 2010;138:2437.
86. Culnan D, Albaugh V, Sun M, et al. Ileal interposition improves glucose tolerance and insulin sensitivity in the obese Zucker rat. Am J Physiol Gastrointest Liver Physiol 2010;299:60.
87. Shah M, Law JH, Micheletto F, et al. The contribution of endogenous glucagon-like peptide-1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes Published Online First: 2 Oct. 2013. doi: 10.2337/db13-0954
88. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16.
89. Wilson-Perez HE, Chambers AP, Ryan KK, et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes 2013;62:2380-5.
90. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941-8. (Pubitemid 37064767)
91. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY (3-36) physiologically inhibits food intake. Nature 2002;418:650-4.
92. Yousseif A, Emmanuel J, Karra E, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg Published Online First: 31 Aug. 2013. doi: 10.1007/s11695-013-1066-0
93. Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007;92:1754-7. (Pubitemid 46997183)
94. Witte AB, Gryback P, Holst JJ, et al. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept 2009;158:57-62.
95. Nightingale JM, Kamm MA, Van Der Sijp JR, et al. Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying. Gut 1996;39:267-72. (Pubitemid 26276005)
96. Allen JM, Fitzpatrick ML, Yeats JC, et al. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 1984;30:255-62. (Pubitemid 15210438)
97. Stylopoulos N, Hoppin A, Kaplan L. Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity (Silver Spring, Md) 2009;17:1839-47.
98. Zechner J, Mirshahi U, Satapati S, et al. Weight-independent effects of roux-en-Y gastric bypass on glucose homeostasis via melanocortin-4 receptors in mice and humans. Gastroenterology 2013;144:580-90.
99. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011;365:1597-604.
100. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31. (Pubitemid 46018515)
101. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-23. (Pubitemid 39473554)
102. Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005;102:11070-5. (Pubitemid 41105994)
103. Zhang H, Di Baise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009;106:2365-70.
104. Li JV, Ashrafian H, Bueter M, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 2011;60:1214-23.
105. Liou AP, Paziuk M, Luevano JM Jr et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013;5:178ra41.
106. Aron-Wisnewsky J, Dore J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol 2012;9:590-8.
107. Abu Dayyeh BK, Thompson CC. Obesity and bariatrics for the endoscopist: new techniques. Therap Adv Gastroenterol 2011;4:433-42.
108. Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc 2010;71:976-82.
109. Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 2010;251:236-43.
110. Cohen RV, Neto MG, Correa JL, et al. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab 2013;98:E279-82.
111. De Jonge C, Rensen SS, Koek GH, et al. Endoscopic Duodenal-Jejunal Bypass Liner Rapidly Improves Plasma Parameters of Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2013;11:1517-20.
112. De Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg 2013;23:1354-60.
113. Habegger KM, Al-Massadi O, Heppner KM, et al. Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. Gut Published Online First: 9 Oct. 2013. doi: 10.1136/gutjnl-2013-304583
114. Cohen R, Le Roux CW, Papamargaritis D, et al. Role of proximal gut exclusion from food on glucose homeostasis in patients with Type 2 diabetes. Diabet Med 2013;30:1482-6.
115. Abu Dayyeh B, Rajan E, Gostout C. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc 2013;78:530-5.